These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 15483021

  • 1. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R.
    J Clin Oncol; 2004 Oct 15; 22(20):4119-26. PubMed ID: 15483021
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.
    Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH.
    J Clin Oncol; 2004 Apr 15; 22(8):1398-403. PubMed ID: 15007087
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
    Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G.
    Pediatr Blood Cancer; 2006 Nov 15; 47(6):790-4. PubMed ID: 16435380
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.
    Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, Prete A, Mastrangelo S, Podda M, Haupt R, De Bernardi B.
    Cancer; 2003 Dec 01; 98(11):2488-94. PubMed ID: 14635085
    [Abstract] [Full Text] [Related]

  • 6. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
    Bolis G, Scarfone G, Tateo S, Mangili G, Villa A, Parazzini F.
    Gynecol Oncol; 2001 Jan 01; 80(1):13-5. PubMed ID: 11136562
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.
    Stathopoulos GP, Katis C, Tsavdaridis D, Dimitroulis J, Karaindros D, Stathopoulos J, Dimou E.
    Cancer Chemother Pharmacol; 2006 Oct 01; 58(4):555-60. PubMed ID: 16520987
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H.
    Pediatr Blood Cancer; 2006 Nov 01; 47(6):795-800. PubMed ID: 16411206
    [Abstract] [Full Text] [Related]

  • 14. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou Ch, Stathopoulos J, Skarlos D.
    Cancer Chemother Pharmacol; 2007 Jun 01; 60(1):123-8. PubMed ID: 17111119
    [Abstract] [Full Text] [Related]

  • 15. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
    Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, Rubie H, Coze C, Plantaz D, Bernard F, Chastagner P, Bouzy J, Hartmann O.
    J Clin Oncol; 2005 Jan 20; 23(3):532-40. PubMed ID: 15659499
    [Abstract] [Full Text] [Related]

  • 16. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
    De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo P, Bruzzi P, Italian Co-Operative Group for Neuroblastoma.
    J Clin Oncol; 2003 Apr 15; 21(8):1592-601. PubMed ID: 12697885
    [Abstract] [Full Text] [Related]

  • 17. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
    London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L.
    J Clin Oncol; 2010 Aug 20; 28(24):3808-15. PubMed ID: 20660830
    [Abstract] [Full Text] [Related]

  • 18. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.
    J Clin Oncol; 2007 Mar 20; 25(9):1054-60. PubMed ID: 17369569
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N, Stewart CF, Zhou Y, Campana D, Coustan-Smith E, Rivera GK, Relling MV, Pui CH, Gajjar A.
    Cancer; 2008 May 01; 112(9):1983-91. PubMed ID: 18318429
    [Abstract] [Full Text] [Related]

  • 20. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G.
    J Clin Oncol; 2007 May 20; 25(15):2086-92. PubMed ID: 17513814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.